Aquestive Therapeutics, Inc. (AQST)
USD 3.46
(-10.13%)
USD 3.46
(-10.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 50.58 Million | 47.68 Million | 50.83 Million | 45.84 Million | 52.6 Million | 67.43 Million |
| Cost of Revenue | 20.83 Million | 19.38 Million | 14.98 Million | 12.96 Million | 20.36 Million | 20.98 Million |
| Gross Profit | 29.75 Million | 28.29 Million | 35.84 Million | 32.88 Million | 32.24 Million | 46.44 Million |
| Operating Expenses | 44.85 Million | 70.36 Million | 70.52 Million | 75.77 Million | 84.91 Million | 95.37 Million |
| Selling, General and Administrative Expenses | 31.75 Million | 52.87 Million | 53.47 Million | 55.89 Million | 64.34 Million | 72.26 Million |
| Research and Development Expenses | 13.1 Million | 17.48 Million | 17.04 Million | 19.88 Million | 20.57 Million | 23.11 Million |
| Other Expenses | - | - | - | - | - | -5000.00 |
| Cost and Expenses | 65.68 Million | 89.74 Million | 85.51 Million | 88.74 Million | 105.27 Million | 116.36 Million |
| Operating Income | -15.1 Million | -42.06 Million | -34.67 Million | -42.89 Million | -52.66 Million | -48.93 Million |
| Interest Expense | 7.46 Million | 12.44 Million | 22.46 Million | 13.02 Million | 9.31 Million | 7.71 Million |
| Income Tax Expense | 245 Thousand | 5.79 Million | 19.49 Million | 9.57 Million | 6.41 Million | -4.73 Million |
| Earnings before Tax | -7.62 Million | -54.41 Million | -70.53 Million | -55.78 Million | -66.24 Million | -61.37 Million |
| Net Income | -7.87 Million | -60.2 Million | -90.03 Million | -65.36 Million | -72.65 Million | -61.37 Million |
| Earnings Per Share Basic | -0.13 | -1.24 | -2.36 | -1.94 | -2.87 | -2.96 |
| Earnings Per Share Diluted | -0.13 | -1.24 | -2.36 | -1.94 | -2.87 | -2.96 |
| Weighted Average Shares Outstanding | 61.25 Million | 48.73 Million | 38.07 Million | 33.65 Million | 25.35 Million | 20.72 Million |
| Weighted Average Shares Outstanding (Diluted) | 61.25 Million | 48.73 Million | 38.07 Million | 33.65 Million | 25.35 Million | 20.72 Million |
| Gross Margin | 0.59 | 0.59 | 0.71 | 0.72 | 0.61 | 0.69 |
| EBIT Margin | 0.02 | -0.88 | -0.67 | -0.93 | -0.99 | -0.72 |
| Profit Margin | -0.16 | -1.26 | -1.77 | -1.43 | -1.38 | -0.91 |
| EBITDA | 1.18 Million | -39.58 Million | -45.11 Million | -39.15 Million | -53.87 Million | -50.32 Million |
| Earnings Before Tax Margin | -0.30 | -0.88 | -0.68 | -0.94 | -1.00 | -0.73 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 13.54 Million | 20.09 Million | 12.05 Million | 50.58 Million | 13.2 Million | 13 Million |
| Cost of Revenue | - | 4.52 Million | 4.38 Million | 20.61 Million | 4.67 Million | 4.79 Million |
| Gross Profit | 13.54 Million | 15.57 Million | 7.66 Million | 29.96 Million | 8.52 Million | 8.2 Million |
| Operating Expenses | 17.39 Million | 15.51 Million | 16.62 Million | 44.85 Million | 12.43 Million | 10.58 Million |
| Selling, General and Administrative Expenses | 12.12 Million | 11.35 Million | 10.68 Million | - | 9.55 Million | 7.38 Million |
| Research and Development Expenses | 5.26 Million | 4.16 Million | 5.93 Million | - | 2.88 Million | 3.19 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 21.83 Million | 20.04 Million | 21.01 Million | 65.46 Million | 17.11 Million | 15.37 Million |
| Operating Income | -8.29 Million | 55 Thousand | -8.95 Million | -14.88 Million | -3.91 Million | -2.37 Million |
| Interest Expense | -2.78 Million | 4.19 Million | 4.2 Million | 7.46 Million | 3.23 Million | -1.25 Million |
| Income Tax Expense | - | - | 163.72 Thousand | 245 Thousand | 101 Thousand | -140 Thousand |
| Earnings before Tax | -11.5 Million | -2.74 Million | -12.82 Million | -7.62 Million | -8.01 Million | -2.17 Million |
| Net Income | -11.5 Million | -2.74 Million | -12.82 Million | -7.87 Million | -8.11 Million | -2.03 Million |
| Earnings Per Share Basic | -0.13 | -0.03 | -0.17 | - | -0.12 | -0.03 |
| Earnings Per Share Diluted | -0.13 | -0.03 | -0.17 | - | -0.12 | -0.03 |
| Weighted Average Shares Outstanding | 91.08 Million | 90.91 Million | 73.61 Million | 61.25 Million | 68.53 Million | 64.67 Million |
| Weighted Average Shares Outstanding (Diluted) | 91.08 Million | 90.91 Million | 73.61 Million | 61.25 Million | 68.53 Million | 64.67 Million |
| Gross Margin | 1.00 | 0.77 | 0.64 | 0.59 | 0.65 | 0.63 |
| EBIT Margin | -0.61 | 0.01 | -0.73 | - | -0.26 | -0.18 |
| Profit Margin | -0.85 | -0.14 | -1.06 | -0.16 | -0.61 | -0.16 |
| EBITDA | -8.29 Million | 260 Thousand | -8.75 Million | - | -3.44 Million | -2.37 Million |
| Earnings Before Tax Margin | -0.61 | 0.00 | -0.74 | -0.29 | -0.30 | -0.18 |
RFLL
GENE
QIAN
SGMT
ALEGF
SXYAY